FLHLF News and Press, Filament Health From 01/05/22

FILAMENT HEALTH RECOGNIZES THE RESTORATION OF ACCESS TO RESTRICTED DRUGS VIA THE HEALTH CANADA SPECIAL ACCESS PROGRAM Canada NewsWire VANCOUVER, BC , Jan. 5, 2022 /CNW/ - Filament Health Corp. ( OTCQB:FLHLF ) ( NEO:FH ) ( FSE:7...

Additional Phase 2 Study Announced. Filament announced that Health Canada approved a new Phase 2 clinical trial to test PEX010 in persistent depressive disorder (PDD). The trial will test a 1 milligram microdose of PEX010 against placebo to determine safety and efficacy of the microdosing. Stu...

FILAMENT HEALTH ANNOUNCES HEALTH CANADA APPROVAL FOR PHASE II TRIAL ADMINISTERING NEW PSILOCYBIN MICRODOSE FORMULATION Canada NewsWire The clinical trial at the University of Toronto will study low doses of psilocybin in healthy subjects with persistent depressiv...

Filament Health Is Developing Natural Psychedelic Botanical Drugs For Psychiatric Conditions. Filament Health has developed proprietary methods for producing naturally occurring psilocybin, psilocin, and other psychoactive compounds from plants and fungi. These compounds have been formulated f...

Filament Health to Participate in Key Psychedelics Conferences in December 2021 Canada NewsWire VANCOUVER, BC , Dec. 1, 2021 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic ...

Filament Health Reports Third Quarter 2021 Financial Results and Operational Highlights Canada NewsWire FDA Authorization of Historic Phase I Clinical Trial Using All-Natural Psychedelic Compounds and Direct Psilocin Administration for the First Time Granted ...

VANCOUVER, BC / ACCESSWIRE / November 3, 2021 / The Power Play by The Market Herald has announced the release of new interviews with Filament Health, Kidoz Inc., Falcon Gold, Psyched Wellness, Maven Brands Inc., and Xali Gold Corp. discussing their latest press releases. The Power Play by T...

Exclusively-natural psychedelic drug discovery company Filament Health Corp. (OTCQB: FLHLF) (NEO: FH)  received authorization from the FDA authorization to initiate the first clinical trial using naturally-sourced psychedelic substances. The news caused the stock to jump over...

Filament Health Announces FDA Authorization of Clinical Trial with First-Ever Direct Psilocin Administration and First-Ever Psychedelic Botanical Drug Candidates Canada NewsWire The Phase 1 Trial is Taking Place at the Translational Psychedelic Research Program at the ...

KCSA Psychedelics Virtual Investor Conference Presentations Available for On-Demand Viewing Individual and institutional investors as well as advisors are invited to log-on to VirtualInvestorConferences.com to view presentations PR Newswire NEW YORK , Oct. 18, ...